Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 2197 to 2208 of 2217 entries
Sorted by: Best Match Show Resources per page
Anti-inflammatory Treatment of Kawasaki Disease: Comparison of Current Guidelines and Perspectives.

Frontiers in medicine

Buda P, Friedman-Gruszczyńska J, Książyk J.
PMID: 34917629
Front Med (Lausanne). 2021 Nov 30;8:738850. doi: 10.3389/fmed.2021.738850. eCollection 2021.

Kawasaki disease (KD), an acute, generalized vasculitis, is associated with an increased risk of coronary heart disease and is the most common cause of acquired heart disease in childhood. The incidence of KD is increasing worldwide. There are numerous...

Cite
Buda P, Friedman-Gruszczyńska J, Książyk J. Anti-inflammatory Treatment of Kawasaki Disease: Comparison of Current Guidelines and Perspectives. Front Med (Lausanne). 2021;8:738850doi: 10.3389/fmed.2021.738850.
Buda, P., Friedman-Gruszczyńska, J., & Książyk, J. (2021). Anti-inflammatory Treatment of Kawasaki Disease: Comparison of Current Guidelines and Perspectives. Frontiers in medicine, 8738850. https://doi.org/10.3389/fmed.2021.738850
Buda, Piotr, et al. "Anti-inflammatory Treatment of Kawasaki Disease: Comparison of Current Guidelines and Perspectives." Frontiers in medicine vol. 8 (2021): 738850. doi: https://doi.org/10.3389/fmed.2021.738850
Buda P, Friedman-Gruszczyńska J, Książyk J. Anti-inflammatory Treatment of Kawasaki Disease: Comparison of Current Guidelines and Perspectives. Front Med (Lausanne). 2021 Nov 30;8:738850. doi: 10.3389/fmed.2021.738850. eCollection 2021. PMID: 34917629; PMCID: PMC8669475.
Copy Download .nbib Format: NLM
A case of multisystem inflammatory syndrome (MIS-A) in an adult woman 18 days after COVID-19 vaccination.

Acta clinica Belgica

Stappers S, Ceuleers B, Van Brusselen D, Willems P, de Tavernier B, Verlinden A.
PMID: 34511054
Acta Clin Belg. 2021 Sep 12;1-6. doi: 10.1080/17843286.2021.1977899. Epub 2021 Sep 12.

We discuss a case of a young woman, presenting a constellation of clinical and biochemical features meeting the current case definition of multisystem inflammatory syndrome in adults (MIS-A), 18 days after receiving her first dose of the Oxford/AstraZeneca vaccine....

Cite
Stappers S, Ceuleers B, Van Brusselen D, et al. A case of multisystem inflammatory syndrome (MIS-A) in an adult woman 18 days after COVID-19 vaccination. Acta Clin Belg. 2021;1-6doi: 10.1080/17843286.2021.1977899.
Stappers, S., Ceuleers, B., Van Brusselen, D., Willems, P., de Tavernier, B., & Verlinden, A. (2021). A case of multisystem inflammatory syndrome (MIS-A) in an adult woman 18 days after COVID-19 vaccination. Acta clinica Belgica, 1-6. https://doi.org/10.1080/17843286.2021.1977899
Stappers, Sofie, et al. "A case of multisystem inflammatory syndrome (MIS-A) in an adult woman 18 days after COVID-19 vaccination." Acta clinica Belgica vol. (2021): 1-6. doi: https://doi.org/10.1080/17843286.2021.1977899
Stappers S, Ceuleers B, Van Brusselen D, Willems P, de Tavernier B, Verlinden A. A case of multisystem inflammatory syndrome (MIS-A) in an adult woman 18 days after COVID-19 vaccination. Acta Clin Belg. 2021 Sep 12;1-6. doi: 10.1080/17843286.2021.1977899. Epub 2021 Sep 12. PMID: 34511054.
Copy Download .nbib Format: NLM
Development of Anti-.

ImmunoTargets and therapy

Lillo AM, Velappan N, Kelliher JM, Watts AJ, Merriman SP, Vuyisich G, Lilley LM, Coombs KE, Mastren T, Teshima M, Stein BW, Wagner GL, Iyer S, Bradbury ARM, Harris JF, Dichosa AE, Kozimor SA.
PMID: 33294421
Immunotargets Ther. 2020 Nov 27;9:299-316. doi: 10.2147/ITT.S267077. eCollection 2020.

METHODS: Here, we describe a set of human monoclonal immunoglobulins (IgG1s) targeting RESULTS: Two of our anti-F1 IgG (αF1Ig 2 and αF1Ig 8) stood out for high production yield, specificity, and stability. These two antibodies were additionally attractive in...

Cite
Lillo AM, Velappan N, Kelliher JM, et al. Development of Anti-. Immunotargets Ther. 2020;9:299-316doi: 10.2147/ITT.S267077.
Lillo, A. M., Velappan, N., Kelliher, J. M., Watts, A. J., Merriman, S. P., Vuyisich, G., Lilley, L. M., Coombs, K. E., Mastren, T., Teshima, M., Stein, B. W., Wagner, G. L., Iyer, S., Bradbury, A. R. M., Harris, J. F., Dichosa, A. E., & Kozimor, S. A. (2020). Development of Anti-. ImmunoTargets and therapy, 9299-316. https://doi.org/10.2147/ITT.S267077
Lillo, Antonietta M, et al. "Development of Anti-." ImmunoTargets and therapy vol. 9 (2020): 299-316. doi: https://doi.org/10.2147/ITT.S267077
Lillo AM, Velappan N, Kelliher JM, Watts AJ, Merriman SP, Vuyisich G, Lilley LM, Coombs KE, Mastren T, Teshima M, Stein BW, Wagner GL, Iyer S, Bradbury ARM, Harris JF, Dichosa AE, Kozimor SA. Development of Anti-. Immunotargets Ther. 2020 Nov 27;9:299-316. doi: 10.2147/ITT.S267077. eCollection 2020. PMID: 33294421; PMCID: PMC7716875.
Copy Download .nbib Format: NLM
Variability of Murine Pregnancy Outcome Resulting from Passive Immunization with Anticardiolipin Antibody-Positive Immunoglobulin G.

Journal of maternal-fetal investigation : the official journal of French Society of Ultrasound in Medicine and Biology ... [et al.]

Silver RK, Russell TL, Brodin AG, Check IJ, Helfand BT, Caplan MS.
PMID: 9524158
J Matern Fetal Investig. 1998 Mar;8(1):35-8.

>Objective: Administration of purified human IgG from antiphospholipid syndrome patients has not consistently caused murine pregnancy loss despite the presence of significant anticardiolipin antibody (ACA) activity. We evaluated whether a correlation exists between ACA activity and the degree of...

Cite
Silver RK, Russell TL, Brodin AG, et al. Variability of Murine Pregnancy Outcome Resulting from Passive Immunization with Anticardiolipin Antibody-Positive Immunoglobulin G. J Matern Fetal Investig. 1998;8(1):35-8
Silver, R. K., Russell, T. L., Brodin, A. G., Check, I. J., Helfand, B. T., & Caplan, M. S. (1998). Variability of Murine Pregnancy Outcome Resulting from Passive Immunization with Anticardiolipin Antibody-Positive Immunoglobulin G. Journal of maternal-fetal investigation : the official journal of French Society of Ultrasound in Medicine and Biology ... [et al.], 8(1), 35-8.
Silver, et al. "Variability of Murine Pregnancy Outcome Resulting from Passive Immunization with Anticardiolipin Antibody-Positive Immunoglobulin G." Journal of maternal-fetal investigation : the official journal of French Society of Ultrasound in Medicine and Biology ... [et al.] vol. 8,1 (1998): 35-8.
Silver RK, Russell TL, Brodin AG, Check IJ, Helfand BT, Caplan MS. Variability of Murine Pregnancy Outcome Resulting from Passive Immunization with Anticardiolipin Antibody-Positive Immunoglobulin G. J Matern Fetal Investig. 1998 Mar;8(1):35-8. PMID: 9524158.
Copy Download .nbib Format: NLM
Changes in lymphocytes, neutrophils and immunoglobulins in year-1 cladribine treatment in multiple sclerosis.

Multiple sclerosis and related disorders

Spiezia AL, Cerbone V, Molinari EA, Capasso N, Lanzillo R, Carotenuto A, Petracca M, Novarella F, Covelli B, Scalia G, Brescia Morra V, Moccia M.
PMID: 34871857
Mult Scler Relat Disord. 2021 Nov 29;57:103431. doi: 10.1016/j.msard.2021.103431. Epub 2021 Nov 29.

No abstract available.

Cite
Spiezia AL, Cerbone V, Molinari EA, et al. Changes in lymphocytes, neutrophils and immunoglobulins in year-1 cladribine treatment in multiple sclerosis. Mult Scler Relat Disord. 2021;57:103431doi: 10.1016/j.msard.2021.103431.
Spiezia, A. L., Cerbone, V., Molinari, E. A., Capasso, N., Lanzillo, R., Carotenuto, A., Petracca, M., Novarella, F., Covelli, B., Scalia, G., Brescia Morra, V., & Moccia, M. (2021). Changes in lymphocytes, neutrophils and immunoglobulins in year-1 cladribine treatment in multiple sclerosis. Multiple sclerosis and related disorders, 57103431. https://doi.org/10.1016/j.msard.2021.103431
Spiezia, Antonio Luca, et al. "Changes in lymphocytes, neutrophils and immunoglobulins in year-1 cladribine treatment in multiple sclerosis." Multiple sclerosis and related disorders vol. 57 (2021): 103431. doi: https://doi.org/10.1016/j.msard.2021.103431
Spiezia AL, Cerbone V, Molinari EA, Capasso N, Lanzillo R, Carotenuto A, Petracca M, Novarella F, Covelli B, Scalia G, Brescia Morra V, Moccia M. Changes in lymphocytes, neutrophils and immunoglobulins in year-1 cladribine treatment in multiple sclerosis. Mult Scler Relat Disord. 2021 Nov 29;57:103431. doi: 10.1016/j.msard.2021.103431. Epub 2021 Nov 29. PMID: 34871857.
Copy Download .nbib Format: NLM
Unbiased interrogation of memory B cells from convalescent COVID-19 patients reveals a broad antiviral humoral response targeting SARS-CoV-2 antigens beyond the spike protein.

Vaccine: X

DiMuzio JM, Heimbach BC, Howanski RJ, Dowling JP, Patel NB, Henriquez N, Nicolescu C, Nath M, Polley A, Bingaman JL, Smith T, Harman BC, Robinson MK, Morin MJ, Nikitin PA.
PMID: 33937741
Vaccine X. 2021 Aug;8:100098. doi: 10.1016/j.jvacx.2021.100098. Epub 2021 Apr 24.

Patients who recover from SARS-CoV-2 infections produce antibodies and antigen-specific T cells against multiple viral proteins. Here, an unbiased interrogation of the anti-viral memory B cell repertoire of convalescent patients has been performed by generating large, stable hybridoma libraries...

Cite
DiMuzio JM, Heimbach BC, Howanski RJ, et al. Unbiased interrogation of memory B cells from convalescent COVID-19 patients reveals a broad antiviral humoral response targeting SARS-CoV-2 antigens beyond the spike protein. Vaccine X. 2021;8:100098doi: 10.1016/j.jvacx.2021.100098.
DiMuzio, J. M., Heimbach, B. C., Howanski, R. J., Dowling, J. P., Patel, N. B., Henriquez, N., Nicolescu, C., Nath, M., Polley, A., Bingaman, J. L., Smith, T., Harman, B. C., Robinson, M. K., Morin, M. J., & Nikitin, P. A. (2021). Unbiased interrogation of memory B cells from convalescent COVID-19 patients reveals a broad antiviral humoral response targeting SARS-CoV-2 antigens beyond the spike protein. Vaccine: X, 8100098. https://doi.org/10.1016/j.jvacx.2021.100098
DiMuzio, Jillian M, et al. "Unbiased interrogation of memory B cells from convalescent COVID-19 patients reveals a broad antiviral humoral response targeting SARS-CoV-2 antigens beyond the spike protein." Vaccine: X vol. 8 (2021): 100098. doi: https://doi.org/10.1016/j.jvacx.2021.100098
DiMuzio JM, Heimbach BC, Howanski RJ, Dowling JP, Patel NB, Henriquez N, Nicolescu C, Nath M, Polley A, Bingaman JL, Smith T, Harman BC, Robinson MK, Morin MJ, Nikitin PA. Unbiased interrogation of memory B cells from convalescent COVID-19 patients reveals a broad antiviral humoral response targeting SARS-CoV-2 antigens beyond the spike protein. Vaccine X. 2021 Aug;8:100098. doi: 10.1016/j.jvacx.2021.100098. Epub 2021 Apr 24. PMID: 33937741; PMCID: PMC8064894.
Copy Download .nbib Format: NLM
Successful Treatment of Vaccine-Induced Immune Thrombotic Thrombocytopenia in a 26-Year-Old Female Patient.

Acta haematologica

Kemper M, Lenz G, Mesters RM.
PMID: 34614491
Acta Haematol. 2021 Oct 06;1-4. doi: 10.1159/000519451. Epub 2021 Oct 06.

Vaccine-induced immune thrombotic thrombocytopenia (VITT) has already been described after vaccination with ChAdOx2 nCov-19 (AstraZeneca) and Ad26.COV2.S (Johnson & Johnson/Janssen). However, less knowledge so far has been gained about optimal therapeutic regimens in VITT-suspected patients. Here, we report the...

Cite
Kemper M, Lenz G, Mesters RM. Successful Treatment of Vaccine-Induced Immune Thrombotic Thrombocytopenia in a 26-Year-Old Female Patient. Acta Haematol. 2021;1-4doi: 10.1159/000519451.
Kemper, M., Lenz, G., & Mesters, R. M. (2021). Successful Treatment of Vaccine-Induced Immune Thrombotic Thrombocytopenia in a 26-Year-Old Female Patient. Acta haematologica, 1-4. https://doi.org/10.1159/000519451
Kemper, Marcel, et al. "Successful Treatment of Vaccine-Induced Immune Thrombotic Thrombocytopenia in a 26-Year-Old Female Patient." Acta haematologica vol. (2021): 1-4. doi: https://doi.org/10.1159/000519451
Kemper M, Lenz G, Mesters RM. Successful Treatment of Vaccine-Induced Immune Thrombotic Thrombocytopenia in a 26-Year-Old Female Patient. Acta Haematol. 2021 Oct 06;1-4. doi: 10.1159/000519451. Epub 2021 Oct 06. PMID: 34614491; PMCID: PMC8678222.
Copy Download .nbib Format: NLM
COVID-19-associated immune-mediated encephalitis mimicking acute-onset Creutzfeldt-Jakob disease.

Annals of clinical and translational neurology

Beretta S, Stabile A, Balducci C, DiFrancesco JC, Patruno A, Rona R, Bombino M, Capraro C, Andreetta F, Cavalcante P, Moda F, Citerio G, Foti G, Bogliun G, Ferrarese C.
PMID: 34825771
Ann Clin Transl Neurol. 2021 Dec;8(12):2314-2318. doi: 10.1002/acn3.51479. Epub 2021 Nov 26.

We report a subtype of immune-mediated encephalitis associated with COVID-19, which closely mimics acute-onset sporadic Creutzfeldt-Jakob disease. A 64-year-old man presented with confusion, aphasia, myoclonus, and a silent interstitial pneumonia. He tested positive for SARS-CoV-2. Cognition and myoclonus rapidly...

Cite
Beretta S, Stabile A, Balducci C, et al. COVID-19-associated immune-mediated encephalitis mimicking acute-onset Creutzfeldt-Jakob disease. Ann Clin Transl Neurol. 2021;8(12):2314-2318doi: 10.1002/acn3.51479.
Beretta, S., Stabile, A., Balducci, C., DiFrancesco, J. C., Patruno, A., Rona, R., Bombino, M., Capraro, C., Andreetta, F., Cavalcante, P., Moda, F., Citerio, G., Foti, G., Bogliun, G., & Ferrarese, C. (2021). COVID-19-associated immune-mediated encephalitis mimicking acute-onset Creutzfeldt-Jakob disease. Annals of clinical and translational neurology, 8(12), 2314-2318. https://doi.org/10.1002/acn3.51479
Beretta, Simone, et al. "COVID-19-associated immune-mediated encephalitis mimicking acute-onset Creutzfeldt-Jakob disease." Annals of clinical and translational neurology vol. 8,12 (2021): 2314-2318. doi: https://doi.org/10.1002/acn3.51479
Beretta S, Stabile A, Balducci C, DiFrancesco JC, Patruno A, Rona R, Bombino M, Capraro C, Andreetta F, Cavalcante P, Moda F, Citerio G, Foti G, Bogliun G, Ferrarese C. COVID-19-associated immune-mediated encephalitis mimicking acute-onset Creutzfeldt-Jakob disease. Ann Clin Transl Neurol. 2021 Dec;8(12):2314-2318. doi: 10.1002/acn3.51479. Epub 2021 Nov 26. PMID: 34825771.
Copy Download .nbib Format: NLM
A review of severe thrombocytopenia in Zika patients - Pathophysiology, treatment and outcome.

Travel medicine and infectious disease

De Pijper CA, Schnyder JL, Stijnis C, Goorhuis A, Grobusch MP.
PMID: 34896327
Travel Med Infect Dis. 2021 Dec 08;45:102231. doi: 10.1016/j.tmaid.2021.102231. Epub 2021 Dec 08.

BACKGROUND: During the 2015 Zika virus infection (ZVI) epidemic swiping through the Americas, few cases of ZVI with severe, potentially life-threatening thrombocytopenia were reported. Platelet transfusion, corticosteroids and intravenous immunoglobulins (IVIG) were in most cases applied as therapeutic options,...

Cite
De Pijper CA, Schnyder JL, Stijnis C, et al. A review of severe thrombocytopenia in Zika patients - Pathophysiology, treatment and outcome. Travel Med Infect Dis. 2021;45:102231doi: 10.1016/j.tmaid.2021.102231.
De Pijper, C. A., Schnyder, J. L., Stijnis, C., Goorhuis, A., & Grobusch, M. P. (2021). A review of severe thrombocytopenia in Zika patients - Pathophysiology, treatment and outcome. Travel medicine and infectious disease, 45102231. https://doi.org/10.1016/j.tmaid.2021.102231
De Pijper, Cornelis Adrianus, et al. "A review of severe thrombocytopenia in Zika patients - Pathophysiology, treatment and outcome." Travel medicine and infectious disease vol. 45 (2021): 102231. doi: https://doi.org/10.1016/j.tmaid.2021.102231
De Pijper CA, Schnyder JL, Stijnis C, Goorhuis A, Grobusch MP. A review of severe thrombocytopenia in Zika patients - Pathophysiology, treatment and outcome. Travel Med Infect Dis. 2021 Dec 08;45:102231. doi: 10.1016/j.tmaid.2021.102231. Epub 2021 Dec 08. PMID: 34896327.
Copy Download .nbib Format: NLM
Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic Agents.

Antibodies (Basel, Switzerland)

van Tetering G, Evers M, Chan C, Stip M, Leusen J.
PMID: 33333967
Antibodies (Basel). 2020 Dec 15;9(4). doi: 10.3390/antib9040070.

In the past three decades, a great interest has arisen in the use of immunoglobulins as therapeutic agents. In particular, since the approval of the first monoclonal antibody Rituximab for B cell malignancies, the progress in the antibody-related therapeutic...

Cite
van Tetering G, Evers M, Chan C, et al. Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic Agents. Antibodies (Basel). 2020;9(4)doi: 10.3390/antib9040070.
van Tetering, G., Evers, M., Chan, C., Stip, M., & Leusen, J. (2020). Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic Agents. Antibodies (Basel, Switzerland), 9(4), . https://doi.org/10.3390/antib9040070
van Tetering, Geert, et al. "Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic Agents." Antibodies (Basel, Switzerland) vol. 9,4 (2020). doi: https://doi.org/10.3390/antib9040070
van Tetering G, Evers M, Chan C, Stip M, Leusen J. Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic Agents. Antibodies (Basel). 2020 Dec 15;9(4). doi: 10.3390/antib9040070. PMID: 33333967; PMCID: PMC7768499.
Copy Download .nbib Format: NLM
Systemic burden and cardiovascular risk to Porphyromonas species in apical periodontitis.

Clinical oral investigations

Jiménez C, Garrido M, Pussinen P, Bordagaray MJ, Fernández A, Vega C, Chaparro A, Hoare A, Hernández M.
PMID: 34313848
Clin Oral Investig. 2021 Jul 27; doi: 10.1007/s00784-021-04083-4. Epub 2021 Jul 27.

OBJECTIVE: Porphyromonas (P.) species (spp.) are a major etiological agent of apical periodontitis (AP), which in turn represents a risk factor for cardiovascular diseases. This study explored the associations between endodontic infection with Porphyromonas species, the systemic bacterial burden,...

Cite
Jiménez C, Garrido M, Pussinen P, et al. Systemic burden and cardiovascular risk to Porphyromonas species in apical periodontitis. Clin Oral Investig. 2021;doi: 10.1007/s00784-021-04083-4.
Jiménez, C., Garrido, M., Pussinen, P., Bordagaray, M. J., Fernández, A., Vega, C., Chaparro, A., Hoare, A., & Hernández, M. (2021). Systemic burden and cardiovascular risk to Porphyromonas species in apical periodontitis. Clinical oral investigations, . https://doi.org/10.1007/s00784-021-04083-4
Jiménez, Constanza, et al. "Systemic burden and cardiovascular risk to Porphyromonas species in apical periodontitis." Clinical oral investigations vol. (2021). doi: https://doi.org/10.1007/s00784-021-04083-4
Jiménez C, Garrido M, Pussinen P, Bordagaray MJ, Fernández A, Vega C, Chaparro A, Hoare A, Hernández M. Systemic burden and cardiovascular risk to Porphyromonas species in apical periodontitis. Clin Oral Investig. 2021 Jul 27; doi: 10.1007/s00784-021-04083-4. Epub 2021 Jul 27. PMID: 34313848.
Copy Download .nbib Format: NLM
Effective presence of antibodies against common human coronavirus in IgG immunoglobulin medicinal products.: Antibodies to common coronaviruses in IgG medicinal products.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Díez JM, Romero C, Gajardo R.
PMID: 34929360
Int J Infect Dis. 2021 Dec 17; doi: 10.1016/j.ijid.2021.12.329. Epub 2021 Dec 17.

BACKGROUND: In these studies, immunoglobulin (IgG) products (IV, IM, SC) prepared from geographically diverse plasma pools were tested for activity against common human coronaviruses (HCoV). Products from plasma obtained from Germany, Czech Republic, Slovak Republic, USA, and Spain were...

Cite
Díez JM, Romero C, Gajardo R. Effective presence of antibodies against common human coronavirus in IgG immunoglobulin medicinal products.: Antibodies to common coronaviruses in IgG medicinal products. Int J Infect Dis. 2021;doi: 10.1016/j.ijid.2021.12.329.
Díez, J. M., Romero, C., & Gajardo, R. (2021). Effective presence of antibodies against common human coronavirus in IgG immunoglobulin medicinal products.: Antibodies to common coronaviruses in IgG medicinal products. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, . https://doi.org/10.1016/j.ijid.2021.12.329
Díez, José María, et al. "Effective presence of antibodies against common human coronavirus in IgG immunoglobulin medicinal products.: Antibodies to common coronaviruses in IgG medicinal products." International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases vol. (2021). doi: https://doi.org/10.1016/j.ijid.2021.12.329
Díez JM, Romero C, Gajardo R. Effective presence of antibodies against common human coronavirus in IgG immunoglobulin medicinal products.: Antibodies to common coronaviruses in IgG medicinal products. Int J Infect Dis. 2021 Dec 17; doi: 10.1016/j.ijid.2021.12.329. Epub 2021 Dec 17. PMID: 34929360; PMCID: PMC8679496.
Copy Download .nbib Format: NLM
Showing 2197 to 2208 of 2217 entries